Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia

Yuzuru Kanakura, Yoshitaka Miyakawa, Paul Wilde, Jonathan Smith, Heinrich Achenbach, Shinichiro Okamoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however, treatment options for patients who become intolerant or refractory to initial treatment are limited. This study sought to determine the efficacy, safety, and tolerability of anagrelide in high-risk Japanese adults with ET who were intolerant or refractory to their first-line CRT. Fifty-three patients were enrolled in the study. Of those, 67.9 % had a platelet response (<60 × 104/µL) and 45.3 % achieved normalization of platelet counts (≤40 × 104/µL) on anagrelide therapy. The median time to platelet count response was 98.5 days and the median time to platelet count normalization was 274.0 days. The median daily dose administered was 1.9 mg/day. The most common adverse events observed during anagrelide treatment were anemia, headache, palpitations, and diarrhea. The majority of these were either mild or moderate in severity. Overall, the safety profile of anagrelide in high-risk Japanese patients with ET was consistent with the European Summary of Product Characteristics.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalInternational Journal of Hematology
Volume100
Issue number4
DOIs
Publication statusPublished - 2014 Oct 9

Fingerprint

Essential Thrombocythemia
Safety
Platelet Count
Therapeutics
Blood Platelets
anagrelide
Headache
Anemia
Diarrhea
Japan
Guidelines

Keywords

  • Anagrelide
  • Essential thrombocythemia
  • Japan
  • Second-line treatment

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. / Kanakura, Yuzuru; Miyakawa, Yoshitaka; Wilde, Paul; Smith, Jonathan; Achenbach, Heinrich; Okamoto, Shinichiro.

In: International Journal of Hematology, Vol. 100, No. 4, 09.10.2014, p. 353-360.

Research output: Contribution to journalArticle

@article{a5173749ea484923a0f49cb65c82e578,
title = "Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia",
abstract = "Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however, treatment options for patients who become intolerant or refractory to initial treatment are limited. This study sought to determine the efficacy, safety, and tolerability of anagrelide in high-risk Japanese adults with ET who were intolerant or refractory to their first-line CRT. Fifty-three patients were enrolled in the study. Of those, 67.9 {\%} had a platelet response (<60 × 104/µL) and 45.3 {\%} achieved normalization of platelet counts (≤40 × 104/µL) on anagrelide therapy. The median time to platelet count response was 98.5 days and the median time to platelet count normalization was 274.0 days. The median daily dose administered was 1.9 mg/day. The most common adverse events observed during anagrelide treatment were anemia, headache, palpitations, and diarrhea. The majority of these were either mild or moderate in severity. Overall, the safety profile of anagrelide in high-risk Japanese patients with ET was consistent with the European Summary of Product Characteristics.",
keywords = "Anagrelide, Essential thrombocythemia, Japan, Second-line treatment",
author = "Yuzuru Kanakura and Yoshitaka Miyakawa and Paul Wilde and Jonathan Smith and Heinrich Achenbach and Shinichiro Okamoto",
year = "2014",
month = "10",
day = "9",
doi = "10.1007/s12185-014-1631-x",
language = "English",
volume = "100",
pages = "353--360",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia

AU - Kanakura, Yuzuru

AU - Miyakawa, Yoshitaka

AU - Wilde, Paul

AU - Smith, Jonathan

AU - Achenbach, Heinrich

AU - Okamoto, Shinichiro

PY - 2014/10/9

Y1 - 2014/10/9

N2 - Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however, treatment options for patients who become intolerant or refractory to initial treatment are limited. This study sought to determine the efficacy, safety, and tolerability of anagrelide in high-risk Japanese adults with ET who were intolerant or refractory to their first-line CRT. Fifty-three patients were enrolled in the study. Of those, 67.9 % had a platelet response (<60 × 104/µL) and 45.3 % achieved normalization of platelet counts (≤40 × 104/µL) on anagrelide therapy. The median time to platelet count response was 98.5 days and the median time to platelet count normalization was 274.0 days. The median daily dose administered was 1.9 mg/day. The most common adverse events observed during anagrelide treatment were anemia, headache, palpitations, and diarrhea. The majority of these were either mild or moderate in severity. Overall, the safety profile of anagrelide in high-risk Japanese patients with ET was consistent with the European Summary of Product Characteristics.

AB - Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however, treatment options for patients who become intolerant or refractory to initial treatment are limited. This study sought to determine the efficacy, safety, and tolerability of anagrelide in high-risk Japanese adults with ET who were intolerant or refractory to their first-line CRT. Fifty-three patients were enrolled in the study. Of those, 67.9 % had a platelet response (<60 × 104/µL) and 45.3 % achieved normalization of platelet counts (≤40 × 104/µL) on anagrelide therapy. The median time to platelet count response was 98.5 days and the median time to platelet count normalization was 274.0 days. The median daily dose administered was 1.9 mg/day. The most common adverse events observed during anagrelide treatment were anemia, headache, palpitations, and diarrhea. The majority of these were either mild or moderate in severity. Overall, the safety profile of anagrelide in high-risk Japanese patients with ET was consistent with the European Summary of Product Characteristics.

KW - Anagrelide

KW - Essential thrombocythemia

KW - Japan

KW - Second-line treatment

UR - http://www.scopus.com/inward/record.url?scp=84919658688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919658688&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1631-x

DO - 10.1007/s12185-014-1631-x

M3 - Article

VL - 100

SP - 353

EP - 360

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -